UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
_________________________
FORM 10-Q
_________________________
QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the quarterly period ended October 31, 2019
or
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the transition period from __________ to __________
Commission file number 0-5286
_________________________
KEWAUNEE SCIENTIFIC CORPORATION
(Exact name of registrant as specified in its charter)
_________________________
Delaware
 
38-0715562
(State or other jurisdiction of
incorporation or organization)
 
(IRS Employer
Identification No.)
 
 
2700 West Front Street
Statesville, North Carolina
 
28677-2927
(Address of principal executive offices)
 
(Zip Code)

Registrant’s telephone number, including area code: (704) 873-7202
Securities registered pursuant to Section 12(b) of the Act:

Title of Each Class            Trading Symbol(s)    Name of Exchange on which registered
Common Stock,$2.50 par value                 KEQU             NASDAQ Global Market
            
_________________________
Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.    Yes  ☒    No  ☐
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).    Yes  ☒    No  ☐
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.
Large accelerated filer
 
  
Accelerated filer
 
Non-accelerated filer
 
☐ 
  
Smaller reporting company
 
 
 
 
  
Emerging growth company
 
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ☐
Indicate by check mark whether the registrant is a shell company (as defined by Rule 12b-2 of the Exchange Act).    Yes  ☐    No  ☒
As of December 10, 2019, the registrant had outstanding 2,750,143 shares of Common Stock.
 




KEWAUNEE SCIENTIFIC CORPORATION
INDEX TO FORM 10-Q
FOR THE QUARTERLY PERIOD ENDED OCTOBER 31, 2019
 
 
Page Number
 
 
 
1
 
2
 
3
 
4
 
5
 
6
13
15
15
 
16
17

i



Part 1. Financial Information
Item 1.
Financial Statements

Kewaunee Scientific Corporation
Condensed Consolidated Statements of Operations
(Unaudited)
($ and shares in thousands, except per share amounts)
 
Three Months Ended
October 31,
 
Six Months Ended
October 31,
 
2019
 
2018
 
2019
 
2018
Net sales
$
39,722

 
$
37,278

 
$
79,058

 
$
79,430

Cost of products sold
33,406

 
29,614

 
65,796

 
64,183

Gross profit
6,316

 
7,664

 
13,262

 
15,247

Operating expenses
6,355

 
5,963

 
12,525

 
11,726

Operating earnings (loss)
(39
)
 
1,701

 
737

 
3,521

Other income
16

 
150

 
72

 
314

Interest expense, net
(135
)
 
(91
)
 
(302
)
 
(182
)
Earnings (loss) before income taxes
(158
)
 
1,760

 
507

 
3,653

Income tax expense
2,003

 
388

 
2,172

 
783

Net earnings (loss)
(2,161
)
 
1,372

 
(1,665
)
 
2,870

Less: net earnings attributable to the noncontrolling interest
17

 
40

 
42

 
49

Net earnings (loss) attributable to Kewaunee Scientific Corporation
$
(2,178
)
 
$
1,332

 
$
(1,707
)
 
$
2,821

Net earnings (loss) per share attributable to Kewaunee Scientific Corporation stockholders
 
 
 
 
 
 
 
Basic
$
(0.79
)
 
$
0.49

 
$
(0.62
)
 
$
1.03

Diluted
$
(0.79
)
 
$
0.48

 
$
(0.62
)
 
$
1.01

Weighted average number of common shares outstanding
 
 
 
 
 
 
 
Basic
2,750

 
2,743

 
2,750

 
2,740

Diluted
2,750

 
2,800

 
2,750

 
2,802










See accompanying notes to condensed consolidated financial statements.

1



Kewaunee Scientific Corporation
Condensed Consolidated Statements of Comprehensive Income
(Unaudited)
($ in thousands)
 
Three Months Ended
October 31,
 
Six Months Ended
October 31,
 
2019
 
2018
 
2019
 
2018
Net earnings (loss)
$
(2,161
)
 
$
1,372

 
$
(1,665
)
 
$
2,870

Other comprehensive income (loss), net of tax:
 
 
 
 
 
 
 
Foreign currency translation adjustments
(179
)
 
(725
)
 
17

 
(1,113
)
Change in fair value of cash flow hedge
2

 
1

 
1

 
5

Other comprehensive income (loss)
(177
)
 
(724
)
 
18

 
(1,108
)
Comprehensive income (loss), net of tax
(2,338
)
 
648

 
(1,647
)
 
1,762

Less: comprehensive income attributable to the noncontrolling interest
17

 
40

 
42

 
49

Comprehensive income (loss) attributable to Kewaunee Scientific Corporation
$
(2,355
)
 
$
608

 
$
(1,689
)
 
$
1,713






















See accompanying notes to condensed consolidated financial statements.

2



Kewaunee Scientific Corporation
Condensed Consolidated Statements of Stockholders’ Equity
(Unaudited)
($ in thousands, except share and per share amounts)
 
Common
Stock
 
Additional
Paid-in
Capital
 
Treasury
Stock
 
Retained
Earnings
 
Accumulated
Other
Comprehensive
Income (Loss)
 
Total
Stockholders’
Equity
Balance at April 30, 2019
$
6,875

 
$
3,133

 
$
(53
)
 
$
43,552

 
$
(6,407
)
 
$
47,100

Net earnings attributable to Kewaunee Scientific Corporation

 

 

 
471

 

 
471

Other comprehensive income

 

 

 

 
195

 
195

Cash dividends paid, $0.19 per share

 

 

 
(522
)
 

 
(522
)
Stock based compensation
9

 
51

 

 

 

 
60

Balance at July 31, 2019
$
6,884

 
$
3,184

 
$
(53
)
 
$
43,501

 
$
(6,212
)
 
$
47,304

Net earnings (loss) attributable to Kewaunee Scientific Corporation

 

 

 
(2,178
)
 

 
(2,178
)
Other comprehensive income

 

 

 

 
(177
)
 
(177
)
Cash dividends paid, $0.19 per share

 

 

 
(523
)
 

 
(523
)
Stock based compensation

 
42

 

 

 

 
42

Balance at October 31, 2019
$
6,884

 
$
3,226

 
$
(53
)
 
$
40,800

 
$
(6,389
)
 
$
44,468

 
Common
Stock
 
Additional
Paid-in
Capital
 
Treasury
Stock
 
Retained
Earnings
 
Accumulated
Other
Comprehensive
Income (Loss)
 
Total
Stockholders’
Equity
Balance at April 30, 2018
$
6,841

 
$
3,006

 
$
(53
)
 
$
43,836

 
$
(5,900
)
 
$
47,730

Net earnings attributable to Kewaunee Scientific Corporation

 

 

 
1,489

 

 
1,489

Other comprehensive loss

 

 

 

 
(384
)
 
(384
)
Cash dividends paid, $0.17 per share

 

 

 
(465
)
 

 
(465
)
Stock options exercised, 9,250 shares
13

 
(13
)
 

 

 

 

Stock based compensation
7

 
99

 

 

 

 
106

Cumulative adjustment for ASC 606, net of tax

 

 

 
217

 

 
217

Balance at July 31, 2018
$
6,861

 
$
3,092

 
$
(53
)
 
$
45,077

 
$
(6,284
)
 
$
48,693

Net earnings attributable to Kewaunee Scientific Corporation
$

 
$

 
$

 
$
1,332

 
$

 
$
1,332

Other comprehensive loss

 

 

 

 
(724
)
 
(724
)
Cash dividends paid, $0.19 per share

 

 

 
(521
)
 

 
(521
)
Stock options exercised, 5,800 shares
8

 
(8
)
 

 

 

 

Stock based compensation

 
140

 

 

 

 
140

Cumulative adjustment for ASC 606, net of tax

 

 

 
671

 

 
671

Balance at October 31, 2018
$
6,869

 
$
3,224

 
$
(53
)
 
$
46,559

 
$
(7,008
)
 
$
49,591






See accompanying notes to condensed consolidated financial statements.

3



Kewaunee Scientific Corporation
Condensed Consolidated Balance Sheets
($ and shares in thousands, except per share amounts)
 
October 31,
2019
 
April 30,
2019
 
(Unaudited)
 
 
Assets
 
 
 
Current Assets:
 
 
 
Cash and cash equivalents
$
7,647

 
$
10,647

Restricted cash
1,951

 
509

Receivables, less allowance; $427; $361, on each respective date
32,017

 
33,259

Inventories
14,778

 
17,206

Prepaid expenses and other current assets
4,674

 
3,736

Total Current Assets
61,067

 
65,357

Property, plant and equipment, at cost
57,359

 
56,676

Accumulated depreciation
(41,475
)
 
(40,214
)
Net Property, Plant and Equipment
15,884

 
16,462

Right of use assets
10,082

 

Deferred income taxes
102

 
1,829

Other assets
3,187

 
3,575

Total Other Assets
13,371

 
5,404

Total Assets
$
90,322

 
$
87,223

Liabilities and Stockholders’ Equity
 
 
 
Current Liabilities:
 
 
 
Short-term borrowings and interest rate swaps
$
6,760

 
$
9,513

Current portion of long-term debt

 
1,167

Current portion of capital lease liability
18

 
17

Current portion of operating lease liabilities
1,401

 

Accounts payable
13,836

 
15,190

Employee compensation and amounts withheld
3,788

 
3,737

Deferred revenue
2,032

 
1,599

Other accrued expenses
2,391

 
1,510

Total Current Liabilities
30,226

 
32,733

Long-term debt

 
97

Long-term portion of capital lease liability
123

 
132

Long-term portion of operating lease liabilities
8,513

 

Accrued pension and deferred compensation costs
5,592

 
5,878

Other non-current liabilities
878

 
680

Total Liabilities
45,332

 
39,520

Commitments and Contingencies

 

Stockholders’ Equity:
 
 
 
Common stock, $2.50 par value, Authorized – 5,000 shares; Issued – 2,753 shares; 2,750 shares; – Outstanding – 2,750 shares; 2,747 shares, on each respective date
6,884

 
6,875

        Additional paid-in-capital
3,226

 
3,133

Retained earnings
40,800

 
43,552

Accumulated other comprehensive loss
(6,389
)
 
(6,407
)
Common stock in treasury, at cost, 3 shares, on each date
(53
)
 
(53
)
Total Kewaunee Scientific Corporation Stockholders’ Equity
44,468

 
47,100

Noncontrolling interest
522

 
603

Total Stockholders’ Equity
44,990

 
47,703

Total Liabilities and Stockholders’ Equity
$
90,322

 
$
87,223

See accompanying notes to condensed consolidated financial statements.

4



Kewaunee Scientific Corporation
Condensed Consolidated Statements of Cash Flows
(Unaudited)
($ in thousands)
 
Six Months Ended
October 31,
 
2019
 
2018
Cash flows from operating activities:
 
 
 
Net earnings (loss)
$
(1,665
)
 
$
2,870

Adjustments to reconcile net earnings to net cash provided by (used in) operating activities:
 
 
 
Depreciation
1,292

 
1,263

Bad debt provision
72

 
20

Stock based compensation expense
115

 
275

Provision for deferred income taxes
1,727

 
143

Change in assets and liabilities:
 
 
 
Receivables
1,171

 
2,855

Inventories
2,428

 
565

Accounts payable and other accrued expenses
(223
)
 
(4,202
)
Deferred revenue
433

 
(321
)
Other, net
(854
)
 
(1,167
)
Net cash provided by operating activities
4,496

 
2,301

Cash flows from investing activities:
 
 
 
Capital expenditures
(715
)
 
(1,311
)
Net cash used in investing activities
(715
)
 
(1,311
)
Cash flows from financing activities:
 
 
 
Dividends paid
(1,045
)
 
(986
)
Dividends paid to noncontrolling interest in subsidiaries
(89
)
 

Proceeds from short-term borrowings
31,456

 
34,135

Repayments on short-term borrowings
(34,209
)
 
(33,362
)
Payments on long-term debt and lease obligations
(1,273
)
 
(583
)
Net proceeds from exercise of stock options
(14
)
 
(29
)
Net cash used in financing activities
(5,174
)
 
(825
)
Effect of exchange rate changes on cash and cash equivalents
(165
)
 
(967
)
Increase (decrease) in cash, cash equivalents and restricted cash
(1,558
)
 
(802
)
Cash, cash equivalents and restricted cash, beginning of period
11,156

 
10,958

Cash, cash equivalents and restricted cash, end of period
$
9,598

 
$
10,156












See accompanying notes to condensed consolidated financial statements.

5



Kewaunee Scientific Corporation
Notes to Condensed Consolidated Financial Statements
(unaudited)
A. Financial Information
The unaudited interim condensed consolidated financial statements of Kewaunee Scientific Corporation (the “Company”) have been prepared pursuant to the rules and regulations of the Securities and Exchange Commission (the “Commission”). Accordingly, certain information and footnote disclosures normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States of America have been condensed or omitted, although the Company believes that the disclosures are adequate to make the information presented not misleading.
These interim condensed consolidated financial statements include all adjustments (consisting of normal recurring adjustments) necessary for a fair presentation of these financial statements and should be read in conjunction with the consolidated financial statements and notes included in the Company’s 2019 Annual Report on Form 10-K. The results of operations for the interim periods are not necessarily indicative of the results of operations to be expected for the full year. The condensed consolidated balance sheet as of April 30, 2019 included in this interim period filing has been derived from the audited financial statements at that date, but does not include all of the information and related notes required by generally accepted accounting principles ("GAAP") for complete financial statements.
The preparation of the interim condensed consolidated financial statements requires management to make certain estimates and assumptions that affect reported amounts and disclosures. Actual results could differ from those estimates.

B. Cash, Cash Equivalents and Restricted Cash
Cash and cash equivalents consist of cash on hand and highly liquid investments with original maturities of three months or less. During the periods ended October 31, 2019 and 2018, the Company had cash deposits in excess of FDIC insured limits. The Company has not experienced any losses from such deposits. Restricted cash includes bank deposits of subsidiaries used for performance guarantees against customer orders.
In accordance with ASU 2016-18, Statement of Cash Flows: Restricted Cash, the Company includes restricted cash along with the cash balance for presentation in the consolidated statements of cash flows. The reconciliation between the consolidated balance sheet and the consolidated statement of cash flows is as follows:
 
 
October 31, 2019
 
October 31, 2018
Cash and cash equivalents
 
$
7,647

 
$
9,477

Restricted cash
 
1,951

 
679

Total cash, cash equivalents and restricted cash
 
$
9,598

 
$
10,156


C. Revenue Recognition
The Company recognizes revenue when control of a good or service promised in a contract (i.e., performance obligation) is transferred to a customer. Control is obtained when a customer has the ability to direct the use of and obtain substantially all of the remaining benefits from that good or service. The majority of the Company’s revenues are recognized over time as the customer receives control as the Company performs work under a contract. However, a portion of the Company’s revenues are recognized at a point-in-time as control is transferred at a distinct point in time per the terms of a contract.
Disaggregated Revenue
A summary of net sales transferred to customers at a point in time and over time for the periods ended October 31, 2019 and October 31, 2018 is as follows (in thousands):

6



 
Three Months Ended October 31, 2019
 
Three months ended October 31, 2018
 
Domestic
 
International
 
Total
 
Domestic
 
International
 
Total
Over Time
$
29,950

 
$
8,138

 
$
38,088

 
$
28,311

 
$
6,656

 
$
34,967

Point in Time
1,634

 

 
1,634

 
2,311

 

 
2,311

 
$
31,584

 
$
8,138

 
$
39,722

 
$
30,622

 
$
6,656

 
$
37,278

 
Six Months Ended October 31, 2019
 
Six Months Ended October 31, 2018
 
Domestic
 
International
 
Total
 
Domestic
 
International
 
Total
Over Time
$
58,185

 
$
18,187

 
$
76,372

 
$
62,559

 
$
12,738

 
$
75,297

Point in Time
2,686

 

 
2,686

 
4,133

 

 
4,133

 
$
60,871

 
$
18,187

 
$
79,058

 
$
66,692

 
$
12,738

 
$
79,430

Contract Balances
The closing and opening balances of contract assets arising from contracts with customers which were recorded as unbilled receivables were $5,116,000 at October 31, 2019 and $4,589,000 at April 30, 2019. The closing and opening balances of contract liabilities arising from contracts with customers were $2,032,000 at October 31, 2019 and $1,599,000 at April 30, 2019. The timing of revenue recognition, billings and cash collections results in accounts receivable, unbilled receivables, and deferred revenue which are disclosed on the consolidated balance sheets and in the notes to the consolidated financial statements. In general, the Company receives payments from customers based on a billing schedule established in its contracts. Unbilled receivables represent amounts earned which have not yet been billed in accordance with contractually stated billing terms. Receivables are recorded when the right to consideration becomes unconditional and the Company has a right to invoice the customer. Deferred revenue relates to payments received in advance of performance under the contract. Deferred revenue is recognized as revenue as (or when) the Company performs under the contract. Approximately all of the contract liability balances at April 30, 2019 and October 31, 2019 are expected to be recognized as revenue during the respective succeeding 12 months.
D. Inventories
The Company measures inventory using the first-in, first-out ("FIFO") method at the lower of cost and net realizable value. Inventories consisted of the following (in thousands):
 
October 31, 2019
 
April 30, 2019
Finished products
$
3,068

 
$
4,139

Work in process
1,878

 
2,179

Raw materials
9,832

 
10,888

 
$
14,778

 
$
17,206

The Company’s International subsidiaries’ inventories were $2,005,000 at October 31, 2019 and $1,863,000 at April 30, 2019 and are included in the above tables.

7



E. Fair Value of Financial Instruments
The Company’s financial instruments consist primarily of cash and equivalents, mutual funds, cash surrender value of life insurance policies, term loans and short-term borrowings. The carrying value of these assets and liabilities approximate their fair value. The following tables summarize the Company’s fair value hierarchy for its financial assets and liabilities measured at fair value on a recurring basis as of October 31, 2019 and April 30, 2019 (in thousands):
 
 
October 31, 2019
Financial Assets
 
Level 1
 
Level 2
 
Total
Trading securities held in non-qualified compensation plans (1)
 
$
2,514

 
$

 
$
2,514

Cash surrender value of life insurance policies (1)
 

 
76

 
76

Total
 
$
2,514

 
$
76

 
$
2,590

Financial Liabilities
 
 
 
 
 
 
Non-qualified compensation plans (2)
 
$

 
$
3,007

 
$
3,007

Total
 
$

 
$
3,007

 
$
3,007

 
 
April 30, 2019
Financial Assets
 
Level 1
 
Level 2
 
Total
Trading securities held in non-qualified compensation plans (1)
 
$
3,057

 
$

 
$
3,057

Cash surrender value of life insurance policies (1)
 

 
76

 
76

Total
 
$
3,057

 
$
76

 
$
3,133

Financial Liabilities
 
 
 
 
 
 
Non-qualified compensation plans (2)
 
$

 
$
3,519

 
$
3,519

Interest rate swap derivatives
 

 
1

 
1

Total
 
$

 
$
3,520

 
$
3,520

(1)
The Company maintains two non-qualified compensation plans which include investment assets in a rabbi trust. These assets consist of marketable securities, which are valued using quoted market prices multiplied by the number of shares owned, and life insurance policies, which are valued at their cash surrender value.
(2)
Plan liabilities are equal to the individual participants’ account balances and other earned retirement benefits.
F. Derivative Financial Instruments
The Company records derivatives on the condensed consolidated balance sheets at fair value and establishes criteria for designation and effectiveness of hedging relationships. The nature of the Company’s business activities involves the management of various financial and market risks, including those related to changes in interest rates. The Company does not enter into derivative instruments for speculative purposes. In May 2013, the Company entered into an interest rate swap agreement whereby the interest rate payable by the Company on $3,450,000 of outstanding long-term debt was effectively converted to a fixed interest rate of 4.875% for the period beginning May 1, 2013 and ending August 1, 2017. In May 2013, the Company entered into an interest rate swap agreement whereby the interest rate payable by the Company on $2,600,000 of outstanding long-term debt was effectively converted to a fixed interest rate of 4.37% for the period beginning August 1, 2017 and ending May 1, 2020. In May 2013, the Company entered into an interest rate swap agreement whereby the interest rate payable by the Company on $1,218,000 of outstanding long-term debt was effectively converted to a fixed interest rate of 3.07% for the period beginning November 3, 2014 and ending May 1, 2020. The Company entered into these interest rate swap arrangements to mitigate future interest rate risk associated with its long-term debt and has designated these as cash flow hedges. In September 2019, the Company terminated the interest rate swap arrangements in conjunction with the payoff of the outstanding long-term debt.

G. Long-term Debt and Other Credit Arrangements

At October 31, 2019, advances of $6.8 million were outstanding under the Company’s revolving credit facility, compared to advances of $9.5 million outstanding as of April 30, 2019. The Company had standby letters of credit outstanding of $344,000 at October 31, 2019 compared to standby letters of credit outstanding of $5.2 million at April 30, 2019. Amounts available under the $20 million revolving credit facility were $12.9 million and $5.3 million at October 31, 2019 and April 30, 2019, respectively.

8



At April 30, 2019, the Company was not in compliance with all of the financial covenants under the revolving credit facility. The Company received a waiver from its lender with respect to this noncompliance pursuant to a waiver letter executed on June 19, 2019 ("the Waiver Letter"). In connection with the Waiver Letter, the Company entered into a Security Agreement pursuant to which the Company granted a security interest in substantially all of its assets to secure its obligations under the Loan Agreement. On July 9, 2019, the Company entered into an amendment to the Loan Agreement and the Line of Credit to effect a change in the financial covenants set forth in the Loan Agreement.  This amendment did not change the amount of availability provided by the Company’s Line of Credit.

In September 2019, the Company paid off its term loan and terminated its interest rate swap agreements. On December 13, 2019, the Company entered into an amendment to the Loan Agreement and the Line of Credit to effect a change to an asset based lending arrangement based on eligible accounts receivable and inventory, with the available amount not to exceed $20 million through January 31, 2020, and with such maximum amount reduced to $15 million thereafter. This amendment replaced the prior financial covenants with new financial covenants, including minimum monthly liquidity and EBITDA requirements. Additionally, a requirement for the repatriation of foreign cash and restrictions on the payment of dividends were added. At October 31, 2019, the Company was in compliance with all of the then-applicable financial covenants of the agreement.

H. Leases

On May 1, 2019, the Company adopted Accounting Standards Update ("ASU") No. 2016-02, Leases, and all subsequently issued clarifying guidance. Under the new guidance, lessees are required to recognize lease assets and lease liabilities for the rights and obligations created by leased assets previously classified as operating leases. In July 2018, the Financial Accounting Standards Board ("FASB") issued ASU No. 2018-11, which permitted entities to record the impact of adoption using a modified retrospective method with any cumulative effect as an adjustment to retained earnings (accumulated deficit) as opposed to restating comparative periods for the effects of applying the new standard. The Company elected this transition approach; therefore, the Company’s prior period reported results are not restated to include the impact of this adoption. In addition, the Company elected the package of three transition practical expedients which alleviate the requirements to reassess embedded leases, lease classification and initial direct costs for leases that commenced prior to the adoption date. The Company has elected to use the short-term lease recognition exemption for all asset classes. This means, for those leases that qualify, the Company will not recognize right-of-use ("ROU") assets or lease liabilities, and this includes not recognizing ROU assets or lease liabilities for existing short-term leases of those assets. The adoption of this standard did not affect the Condensed Consolidated Statements of Operations and therefore, no cumulative effect adjustment was recorded. The adoption of this standard also did not materially affect the Condensed Consolidated Statements of Cash Flows.
The Company has operating type leases for real estate and equipment in both the U.S. and internationally and a financing lease for a truck in the U.S. At October 31, 2019, ROU assets totaled $10,082,000. Included in the ROU assets was a finance lease with a net value of $134,000 with accumulated amortization totaling $25,000. Operating cash paid to settle lease liabilities was $354,000 for the period ended October 31, 2019. The Company’s leases have remaining lease terms of up to 10 years, some of which may include options to extend the leases for up to 5 years or options to terminate the leases within 1 year. Operating lease expense was $576,000 for the three months ended October 31, 2019, inclusive of period cost for short-term leases, not included in lease liabilities, of $222,000. Operating lease expense was $1,125,000 for the six months ended October 31, 2019, inclusive of period cost for short-term leases, not included in lease liabilities, of $457,000.
At October 31, 2019, the weighted average remaining lease term for the capitalized operating leases was 8.0 years and the weighted average discount rate was 4.1%. For finance leases, the weighted average remaining lease term was 5.9 years and the weighted average discount rate was 10.0%. As most of the Company's leases do not provide an implicit rate, the Company uses its incremental borrowing rate based on the information available at commencement date in determining the present value of lease payments. The Company uses the implicit rate when readily determinable.

9



Future minimum lease payments of non-cancelable leases as of October 31, 2019:
 
 
Operating
 
Financing
Remainder of fiscal 2020
 
$
853

 
$
16

2021
 
1,591

 
32

2022
 
1,543

 
32

2023
 
1,531

 
32

2024
 
1,246

 
31

Thereafter
 
5,198

 
42

Total Minimum Lease Payments
 
$
11,962

 
$
185

Imputed Interest
 
(2,049
)
 
(45
)
Total
 
$
9,913

 
$
140

I. Earnings Per Share
Basic earnings per share is based on the weighted average number of common shares outstanding during the year. Diluted earnings per share reflects the assumed exercise of outstanding options and the conversion of restricted stock units (“RSUs”) under the Company’s various stock compensation plans, except when RSUs and options have an antidilutive effect. There were 85,205 antidilutive RSUs and options outstanding at October 31, 2019. There were no antidilutive RSUs or options outstanding at October 31, 2018. The following is a reconciliation of basic to diluted weighted average common shares outstanding (in thousands):
 
Three Months Ended October 31,
 
Six Months Ended October 31,
 
 
2019
2018
 
2019
2018
 
 
 
 
 
 
Basic
2,750

 
2,743

 
 
2,750

 
2,740

 
Dilutive effect of stock options and RSUs

 
57

 
 

 
62

 
Weighted average common shares outstanding - diluted
2,750

 
2,800

 
 
2,750

 
2,802

 
J. Stock Options and Share-based Compensation
Compensation costs related to stock options and other stock awards granted by the Company are charged against operating expenses during their vesting period, under ASC 718, “Compensation-Stock Compensation”. The Company granted 36,534 RSUs under the 2017 Omnibus Incentive Plan in June 2019. The RSUs include both a service and a performance component, vesting over a three year period. The recognized expense is based upon the vesting period for service criteria and estimated attainment of the performance criteria at the end of the three-year period, based on the ratio of cumulative days incurred to total days over the three year period. The Company recorded share-based compensation expense during the three and six months ended October 31, 2019 of $41,000 and $82,000, respectively, with the remaining estimated share-based compensation expense of $512,000 to be recorded over the remaining vesting periods.
K. Income Taxes
Income tax expense of $2,003,000 and $388,000 was recorded for the three months ended October 31, 2019 and 2018, respectively. Income tax expense of $2,172,000 and $783,000 was recorded for the six months ended October 31, 2019 and 2018, respectively. The effective tax rates were 1,267.7% and 22.0% for the three months ended October 31, 2019 and 2018, respectively. The effective tax rates were 428.4% and 21.4% for the six months ended October 31, 2019 and 2018, respectively. The increase in the effective tax rate for the three-month and six-month periods is primarily due to the change in the Company’s assertion regarding the reinvestment of foreign unremitted earnings and the impact of foreign earnings which are taxed at different tax rates than the US tax rate of 21%, and additional Global Intangible Low-Taxed Income ("GILTI") inclusion in the US.
Effective August 1, 2019, the Company elected to amend the indefinite reinvestment of foreign unremitted earnings position set forth by ASC 740-30-25-17 and dissolve the indefinite reinvestment of unremitted earnings assertion for the Singapore, China, and Kewaunee Labway India Pvt. Ltd. international subsidiaries.

10



The Company included a Dividend Distribution Tax withholding expense, imposed by the India Income Tax Department, at a rate of 20.6% for the three and six months ended October 31, 2019. This expense was comprised of $353,000 of taxes paid for the Kewaunee Labway India Pvt. Ltd. dividend distribution that was paid to the parent company and a $1,730,000 deferred tax liability for the global tax exposure related to all remaining historical unremitted earnings of these international subsidiaries as of October 31, 2019. The Company recorded all deferred tax assets and liabilities related to its outside basis differences in its foreign subsidiaries consistent with ASC 740.
L. Defined Benefit Pension Plans
The Company has non-contributory defined benefit pension plans covering substantially all domestic salaried and hourly employees. These plans were amended as of April 30, 2005; no further benefits have been, or will be, earned under the plans, subsequent to the amendment date, and no additional participants will be added to the plans. There were no Company contributions paid to the plans during the three and six months ended October 31, 2019, and the Company does not expect any contributions to be paid during the remainder of the fiscal year. Contributions of $1,000,000 were paid to the plans during the six months ended October 31, 2018. The Company assumed an expected long-term rate of return of 7.75% for the periods ended October 31, 2019 and October 31, 2018. Pension expense consisted of the following (in thousands):
 
Three Months Ended October 31, 2019
 
Three Months Ended October 31, 2018
Service cost
$
0

 
$
0

Interest cost
208

 
215

Expected return on plan assets
(355
)
 
(362
)
Recognition of net loss
260

 
221

Net periodic pension expense
$
113

 
$
74

 
Six Months Ended October 31, 2019
 
Six Months Ended October 31, 2018
Service cost
$
0

 
$
0

Interest cost
416

 
430

Expected return on plan assets
(710
)
 
(724
)
Recognition of net loss
520

 
442

Net periodic pension expense
$
226

 
$
148

M. Segment Information
The Company’s operations are classified into two business segments: Domestic and International. The Domestic business segment principally designs, manufactures, and installs scientific and technical furniture, including steel and wood laboratory cabinetry, fume hoods, laminate casework, flexible systems, worksurfaces, workstations, workbenches, and computer enclosures. The International business segment, which consists of the Company’s foreign subsidiaries, provides products and services, including facility design, detailed engineering, construction, and project management from the planning stage through testing and commissioning of laboratories. Intersegment transactions are recorded at normal profit margins. All intercompany balances and transactions have been eliminated. Certain corporate expenses shown below have not been allocated to the business segments.
The following tables provide financial information by business segments for the periods ended October 31, 2019 and 2018 (in thousands):
 
Domestic
Operations
 
International
Operations
 
Corporate /
Eliminations
 
Total
Three months ended October 31, 2019
 
 
 
 
 
 
 
Revenues from external customers
$
31,584

 
$
8,138

 
$

 
$
39,722

Intersegment revenues
907

 
641

 
(1,548
)
 

Earnings (loss) before income taxes
$
746

 
$
501

 
$
(1,405
)
 
$
(158
)
Three months ended October 31, 2018
 
 
 
 
 
 
 
Revenues from external customers
$
30,622

 
$
6,656

 
$

 
$
37,278

Intersegment revenues
416

 
1,108

 
(1,524
)
 

Earnings (loss) before income taxes
$
2,837

 
$
705

 
$
(1,782
)
 
$
1,760


11




 
Domestic
Operations
 
International
Operations
 
Corporate /
Eliminations
 
Total
Six months ended October 31, 2019
 
 
 
 
 
 
 
Revenues from external customers
$
60,871

 
$
18,187

 
$

 
$
79,058

Intersegment revenues
3,086

 
1,483

 
(4,569
)
 

Earnings (loss) before income taxes
$
2,306

 
$
1,109

 
$
(2,908
)
 
$
507

Six months ended October 31, 2018
 
 
 
 
 
 
 
Revenues from external customers
$
66,692

 
$
12,738

 
$

 
$
79,430

Intersegment revenues
878

 
1,834

 
(2,712
)
 

Earnings (loss) before income taxes
$
5,945

 
$
1,154

 
$
(3,446
)
 
$
3,653

N. Reclassifications
During the second quarter of fiscal year 2019, the Company changed its method of accounting for its Domestic segment’s inventory from the LIFO method to the FIFO method.  The Company reclassified certain amounts in the condensed consolidated statements of operations, the condensed consolidated statements of comprehensive income, the condensed consolidated statements of stockholders’ equity and the condensed consolidated statements of cash flows for the six-month period ended October 31, 2018 to conform to the current period format.
O. New Accounting Standards
In February 2016, the FASB issued ASU 2016-2, “Leases.” This guidance establishes a ROU model that requires a lessee to record a ROU asset and a lease liability on the balance sheet for all leases with terms longer than 12 months. Leases will be classified as either finance or operating, with classification affecting the pattern of expense recognition in the income statement. A modified retrospective transition approach is required for lessees for capital and operating leases existing at, or entered into after, the beginning of the earliest comparative period presented in the financial statements, with certain practical expedients available. This guidance is effective for fiscal years, and interim periods within those years, beginning after December 15, 2018. The Company adopted this standard effective May 1, 2019. See Note H for a discussion of the impact of adoption of this standard.
In August 2018, the Commission adopted final rules pursuant to Commission Release No. 33-10532, “Disclosure Update and Simplification,” amending certain disclosure requirements that were redundant, duplicative, overlapping, outdated or superseded. In addition, the amendments expanded the disclosure requirements relating to the analysis of stockholders’ equity for interim financial statements. Under the amendments, an analysis of changes in each caption of stockholders’ equity presented in the balance sheet must be provided in a note or separate statement. The analysis should present a reconciliation of the beginning balance to the ending balance of each period for which a statement of income is required to be filed. This final rule became effective on November 5, 2018. The Company adopted this final rule effective for the second quarter of fiscal 2019. The adoption of this standard did not have a significant impact on the Company’s consolidated financial position or results of operations.
In February 2018, the FASB issued ASU 2018-2, “Reclassification of Certain Tax Effects from Accumulated Other Comprehensive Income.” This guidance provides the Company with an option to reclassify stranded tax effects resulting from the Tax Cuts and Jobs Act (the "2017 Tax Act") from accumulated other comprehensive income to retained earnings. This guidance is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2018, with early adoption permitted. The Company adopted this standard effective May 1, 2019 and did not elect to reclassify tax effects as a result of tax reform; therefore, the adoption did not have a significant impact on the Company’s consolidated financial position or results of operations.
In June 2016, the FASB issued ASU 2016-13, “Measurement of Credit Losses on Financial Instruments,” which replaces the current incurred loss method used for determining credit losses on financial assets, including trade receivables, with an expected credit loss method. This guidance is effective for fiscal years, and interim periods within those years, beginning after December 15, 2022. The Company will adopt this standard in fiscal year 2024. The Company does not expect the adoption of this standard to have a significant impact on the Company’s consolidated financial position or results of operations.
P. Subsequent Events

12



In December 2019, the Company initiated a restructuring, which included the addition of a new Vice President of Information Technology to lead the transformation and modernization of the Company's information systems, and a reduction in workforce primarily in its domestic operations to reduce operating expenses on an ongoing basis. This restructuring also included a plan for closure of the Company’s subsidiary in China, a commercial sales organization for the Company’s products in China. The Company expects to record a charge in the range of $385,000 to $535,000 in the third quarter of fiscal year 2020 as a result of the restructuring consisting primarily of hiring and relocation expenses and one-time termination benefits for employee severance and benefits. The majority of these expenses are expected to be paid during the third quarter of fiscal year 2020.

Item 2.
Management’s Discussion and Analysis of Financial Condition and Results of Operations
The Company’s 2019 Annual Report to Stockholders contains management’s discussion and analysis of the Company’s financial condition and results of operations as of and for the year ended April 30, 2019. The following discussion and analysis describes material changes in the Company’s financial condition since April 30, 2019. The analysis of results of operations compares the three and six months ended October 31, 2019 with the comparable periods of the prior year.
Results of Operations
Sales for the quarter were $39,722,000, a 6.6% increase from sales of $37,278,000 in the comparable period of the prior year. Domestic sales for the quarter were $31,584,000, up 3.1% from sales of $30,622,000 in the comparable period of the prior year. International sales for the quarter were $8,138,000, up 22.3% from sales of $6,656,000 in the comparable period of the prior year.  The increase in Domestic sales for the quarter was a result of increased activity in the Company's direct sales markets offsetting weakness in dealer activity. International sales increased year over year as a result of continued deliveries of a large, strategic order in the Middle East. 
Sales for the six months ended October 31, 2019 were $79,058,000, a 0.5% decrease from sales of $79,430,000 in the comparable period of the prior year. Domestic sales for the six-month period were $60,871,000, down 8.7% from sales of $66,692,000 in the comparable period of the prior year.  International sales for the quarter were $18,187,000, up 42.8% from sales of $12,738,000 in the comparable period of the prior year. 
The Company’s order backlog was $92 million at October 31, 2019, as compared to $101 million at October 31, 2018, and $101 million at April 30, 2019. The Company continues to have a strong volume of outstanding quotations globally and is aggressively pursuing these projects.
The gross profit margin for the three months ended October 31, 2019 was 15.9% of sales, as compared to 20.6% of sales in the comparable quarter of the prior year. The gross profit margin for the six months ended October 31, 2019 was 16.8% of sales, as compared to 19.2% of sales in the comparable period of the prior year. The decrease in gross profit margin percentage for the three and six months ended October 31, 2019 was a result of a number of low margin orders that the Company aggressively pursued and secured over the past year, and a strategic Middle East order aggressively secured over two years ago at lower than normal margins.
Operating expenses for the three months ended October 31, 2019 were $6,355,000, or 16.0% of sales, as compared to $5,963,000, or 16.0% of sales, in the comparable period of the prior year. Operating expenses for the six months ended October 31, 2019 were $12,525,000, or 15.8% of sales, as compared to $11,726,000, or 14.8% of sales, in the comparable period of the prior year. The increase in operating expenses for the three and six months ended October 31, 2019 related primarily to higher operating costs in the international segment as the Company made investments in capabilities intended to strengthen its position in the India market.
Interest expense was $135,000 and $302,000 for the three and six months ended October 31, 2019, as compared to $91,000 and $182,000 for the comparable periods of the prior year. The changes in interest expense were primarily attributable to changes in borrowing levels.
Income tax expense of $2,003,000 and $388,000 was recorded for the three months ended October 31, 2019 and 2018, respectively. For the six months ended October 31, 2018 and 2019, income tax expense was $2,172,000 and $783,000, respectively. The effective tax rates were 1,267.7% and 22.0% for the three months ended October 31, 2019 and 2018, respectively. The effective tax rates were 428.4% and 21.4% for the six months ended October 31, 2019 and 2018, respectively. The increase in the effective tax rate for the three-month and six-month periods reflects the impact of foreign earnings which were taxed at different tax rates than the US tax rate of 21% and additional GILTI inclusion in the US.

13



As part the Company’s revised global treasury management strategy, the Company elected to amend the indefinite reinvestment of foreign unremitted earnings position set forth by ASC 740 and dissolve the indefinite reinvestment of unremitted earnings assertion for the Singapore, China, and Kewaunee Labway India Pvt. Ltd. international subsidiaries. Revoking this election provides the Company more flexibility in treasury management to invest in projects intended to improve the Company’s operating performance.
The Company included a Dividend Distribution Tax withholding expense, imposed by the India Income Tax Department, at a rate of 20.6% for the three and six months ended October 31, 2019. This expense was comprised of $353,000 of taxes paid for the Kewaunee Labway India Pvt. Ltd. dividend distribution that was paid to the parent company and a $1,730,000 deferred tax liability for the global tax exposure related to all remaining historical unremitted earnings of these international subsidiaries as of October 31, 2019. The Company will record the Dividend Distribution Tax on all future Kewaunee Labway India Pvt. Ltd. earnings at an estimated rate of 20.6% in addition to the corporate income taxes.
Noncontrolling interests related to the Company’s subsidiaries not 100% owned by the Company reduced net earnings by $17,000 and $42,000 for the three and six months ended October 31, 2019, respectively, as compared to $40,000 and $49,000 for the comparable periods of the prior year. The change in the net earnings attributable to the noncontrolling interest in the current period was due to changes in earnings of the subsidiary in the related period.
Net loss was $2,178,000, or $0.79 per diluted share, for the three months ended October 31, 2019, compared to net earnings of $1,332,000, or $0.48 per diluted share, in the prior year period. Net loss of $1,707,000, or $0.62 per diluted share, were reported for the six months ended October 31, 2019, compared to net earnings of $2,821,000, or $1.01 per diluted share, in the prior year period.
Liquidity and Capital Resources
Historically, the Company’s principal sources of liquidity have been funds generated from operations, supplemented as needed by short-term borrowings under the Company’s revolving credit facility. Additionally, certain machinery and equipment are financed by non-cancellable operating leases. The Company believes that these sources will be sufficient to support ongoing business requirements in the current year, including capital expenditures.
The Company had working capital of $30,841,000 at October 31, 2019, compared to $32,624,000 at April 30, 2019. The ratio of current assets to current liabilities was 2.0-to-1.0 at October 31, 2019, compared to 2.0-to-1.0 at April 30, 2019. At October 31, 2019, advances of $6.8 million were outstanding under the Company’s bank revolving credit facility, compared to advances of $9.5 million outstanding as of April 30, 2019. The Company had standby letters of credit outstanding of $344,000 at October 31, 2019 compared to standby letters of credit outstanding of $5.2 million at April 30, 2019. Amounts available under the $20 million revolving credit facility were $12.9 million and $5.3 million at October 31, 2019 and April 30, 2019, respectively. Total borrowings and interest rate swaps were $6.9 million at October 31, 2019, compared to $10.9 million at April 30, 2019. As previously reported in the reports on Form 8-K filed by the Company on June 21, 2019 and July 11, 2019, and in Note 4 of the Notes to the Consolidated Financial Statements included in the Company's 2019 Annual Report on Form 10-K, during the six months ended October 31, 2019, the Company amended its credit facility and entered into a restated security agreement.
In September 2019, the Company paid off its term loan and terminated its interest rate swap agreements.  On December 13, 2019, the Company entered into an amendment to the Loan Agreement and the Line of Credit to effect a change to an asset based lending arrangement based on eligible accounts receivable and inventory, with the available amount not to exceed $20 million through January 31, 2020, and with such maximum amount reduced to $15 million thereafter. This amendment replaced the prior financial covenants with new financial covenants, including minimum monthly liquidity and EBITDA requirements.  Additionally, a requirement for the repatriation of foreign cash and restrictions on the payments of dividends was added.  At October 31, 2019, the Company was in compliance with all of the then-applicable financial covenants of the agreement. 
The Company’s operations provided cash of $4,496,000 during the six months ended October 31, 2019. Cash was provided primarily by operations and decreases in receivables of $1,171,000 and inventory of $2,428,000. During the six months ended October 31, 2019, the Company used net cash of $715,000 in investing activities, all of which was used for capital expenditures. The Company’s financing activities used cash of $5,174,000 during the six months ended October 31, 2019, primarily for reductions in short-term borrowings of $2,753,000, cash dividends of $1,045,000 paid to stockholders, cash dividends paid to minority interest holders of $89,000 and repayments of $1,273,000 of long-term debt.
Outlook    

14



The Company’s ability to predict future demand for its products continues to be limited given its role as subcontractor or supplier to dealers for subcontractors. Demand for the Company’s products is also dependent upon the number of laboratory construction projects planned and/or current progress in projects already under construction. The Company’s earnings are also impacted by fluctuations in prevailing pricing for projects in the laboratory construction marketplace and increased costs of raw materials, including stainless steel, wood, and epoxy resin, and whether the Company is able to increase product prices to customers in amounts that correspond to such increases without materially and adversely affecting sales. Additionally, since prices are normally quoted on a firm basis in the industry, the Company bears the burden of possible increases in labor and material costs between the quotation of an order and delivery of a product. Looking forward, the third quarter is typically the Company's most challenging quarter as there are fewer manufacturing days than other quarters due to the holidays in the United States and construction projects generally slow down at the end of the calendar year. Our goal is to ensure that the Company's fourth quarter production load is full in order to operate our manufacturing facilitates efficiently, which in turn should drive recovery in profitability.

Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995
This report contains statements that the Company believes to be “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical fact included in this report, including statements regarding the Company’s future financial condition, results of operations, business operations and business prospects, are forward-looking statements. Words such as “anticipate,” “estimate,” “expect,” “project,” “intend,” “plan,” “predict,” “believe” and similar words, expressions and variations of these words and expressions are intended to identify forward-looking statements. All forward-looking statements are subject to important factors, risks, uncertainties and assumptions, including industry and economic conditions that could cause actual results to differ materially from those described in the forward-looking statements. Such factors, risks, uncertainties and assumptions include, but are not limited to, competitive and general economic conditions, both domestically and internationally; changes in customer demands; dependence on customers’ required delivery schedules; risks related to fluctuations in the Company’s operating results from quarter to quarter; risks related to international operations, including foreign currency fluctuations; changes in the legal and regulatory environment; changes in raw materials and commodity costs; and acts of terrorism, war, governmental action, natural disasters and other Force Majeure events. Many important factors that could cause such differences are described under the caption “Risk Factors” in Item 1A in the Company’s 2019 Annual Report on Form 10-K and in Quarterly Reports on Form 10-Q subsequently filed by the Company. These forward-looking statements speak only as of the date of this document. The Company assumes no obligation, and expressly disclaims any obligation, to update any forward-looking statements, whether as a result of new information, future events or otherwise.
Item 3.
Quantitative and Qualitative Disclosures About Market Risk
There are no material changes to the disclosures made on this matter in the Company’s Annual Report on Form 10-K for the fiscal year ended April 30, 2019.
Item 4.
Controls and Procedures
(a) Evaluation of disclosure controls and procedures
An evaluation was performed under the supervision and with the participation of the Company’s management, including the Chief Executive Officer (“CEO”) and Chief Financial Officer (“CFO”), of the effectiveness of the design and operation of the Company’s disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended) as of October 31, 2019. Based on that evaluation, the Company’s management, including the CEO and CFO, concluded that, as of October 31, 2019, the Company’s disclosure controls and procedures were adequate and effective and designed to ensure that all material information required to be filed in this quarterly report is made known to them by others within the Company and its subsidiaries.
(b) Changes in internal controls
There was no significant change in the Company’s internal control over financial reporting that occurred during the most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, the Company’s internal control over financial reporting.

15



PART II. OTHER INFORMATION
Item 6.
Exhibits
 
 
 
 
10.1
 
 
10.83*
 
 
31.1
  
 
31.2
 
 
32.1
  
 
32.2
 
 
101.INS
  
XBRL Instance Document
 
101.SCH
  
XBRL Taxonomy Extension Schema Document
 
101.CAL
  
XBRL Taxonomy Extension Calculation Linkbase Document
 
101.DEF
  
XBRL Taxonomy Extension Definition Linkbase Document
 
101.LAB
  
XBRL Taxonomy Extension Label Linkbase Document
 
101.PRE
  
XBRL Taxonomy Extension Presentation Linkbase Document
 

* The referenced exhibit is a management contract or compensatory plan or arrangement.
    


16



SIGNATURE
Pursuant to the requirements of the Securities and Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
 
 
KEWAUNEE SCIENTIFIC CORPORATION
                             (Registrant)
 
 
 
Date: December 16, 2019
 
By
/s/ Donald T. Gardner III
 
 
 
Donald T. Gardner III
 
 
 
(As duly authorized officer and Vice President, Finance and Chief Financial Officer)

17
12/16/2019 EX-10.1 EX-10.1 2 d846452dex101.htm EX-10.1 Exhibit 10.1 Execution Version EIGHTH AMENDMENT TO CREDIT AND SECURITY AGREEMENT AND FOURTH AMENDMENT TO REVOLVING LINE OF CREDIT NOTE This EIGHTH AMENDMENT TO CREDIT AND SECURITY AGREEMENT AND FOURTH AMENDMENT TO REVOLVING LINE OF CREDIT NOTE (this “Amendment”), dated as of December 13, 2019 (the “Eighth Amendment Effective Date”), is entered into by and between KEWAUNEE SCIENTIFIC CORPORATION, a Delaware corporation (the “Borrower”), and WELLS FARGO BANK, NATIONAL ASSOCIATION (the “Bank”). W I T N E S S E T H: WHEREAS, the Bank has made available to the Borrower certain term loans and lines of credit pursuant to the terms and conditions of (i) that certain Credit and Security Agreement, dated as of May 6, 2013, by and between the Borrower and the Bank, as amended by that certain First Amendment to Credit and Security Agreement dated as of July 9, 2013, as further amended by that certain Second Amendment to Credit and Security Agreement dated as of June 4, 2014, as further amended by that certain Third Amendment to Credit and Security Agreement and First Amendment to Revolving Line of Credit Note dated as of June 3, 2015 (the “Third Amendment”), as further amended by that certain Fourth Amendment to Credit and Security Agreement and Second Amendment to Revolving Line of Credit Note dated as of March 12, 2018 (the “Fourth Amendment”), as further amended by that certain Fifth Amendment to Credit and Security Agreement dated as of April 22, 2019, as further amended by that certain Sixth Amendment to Credit and Security Agreement dated as of May 28, 2019, and as further amended by that certain Seventh Amendment to Credit and Security Agreement and Third Amendment to Revolving Line of Credit Note dated as of July 9, 2019 (the “Seventh Amendment”) (as the same may be further amended, restated, supplemented or otherwise modified from time to time, the “Credit Agreement”), (ii) that certain Revolving Line of Credit Note, dated May 6, 2013, made by the Borrower and payable to the order of the Bank, as amended by the Third Amendment, the Fourth Amendment and the Seventh Amendment (as the same may be further amended, restated, supplemented or otherwise modified from time to time, the “Line of Credit Note”) and (iii) certain other Loan Documents executed in connection therewith, as amended, restated, supplemented or otherwise modified from time to time; WHEREAS, the Borrower has requested that the Bank further amend the Credit Agreement and the Line of Credit Note to (i) effect a change in the available amount of the Line of Credit and (ii) amend certain other terms and provisions of the Credit Agreement, on the terms and conditions set forth herein. https://www.sec.gov/Archives/edgar/data/55529/000119312519314689/d846452dex101.htm 1/17


 
12/16/2019 EX-10.1 NOW, THEREFORE, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged by the parties hereto, the parties hereto hereby agree as follows: Section 1. Specific Amendments to Credit Agreement. The parties hereto agree that the Credit Agreement is amended as follows: (a) Section 1.1(a)(i) of the Credit Agreement is hereby amended and restated in its entirety as follows: “(i) Subject to the terms and conditions of this Agreement, Bank hereby agrees to make advances to Borrower from time to time up to and including February 1, 2021 (the “Expiration Date”), not to exceed at any time the aggregate principal amount of Twenty Million and 00/100 Dollars ($20,000,000.00), provided that, from and after the earlier of (a) January 31, 2020 and (b) the cancellation of the Terminating Letter of Credit, such advances shall not exceed the aggregate principal amount of Fifteen Million and 00/100 Dollars ($15,000,000.00) (“Line of Credit”), the proceeds of which shall be used (a) to refinance existing indebtedness of the Borrower to Bank of America, N.A. and (b) for working capital, the issuance of letters of credit, short term financing of capital equipment, and other general corporate purposes. Borrower’s obligation to repay advances under the Line of Credit shall be evidenced by a promissory note dated as of the Closing Date (“Line of Credit Note”), all terms of which are incorporated herein by this reference.” (b) Section 1.1(a)(iii) of the Credit Agreement is hereby deleted in its entirety. (c) Section 1.1(b) of the Credit Agreement is hereby amended by separating the Section into two subsections, with the existing text to be labeled as subsection (i) and the following subsection (ii) to be inserted thereafter: “(ii) Outstanding borrowings under the Line of Credit, to a maximum of the principal amount set forth in clause (a) of this Section 1.1, shall not at any time exceed an aggregate of eighty percent (80%) of Borrower’s Eligible Accounts Receivable, plus twenty-one percent (21%) of the value of Borrower’s eligible inventory (including unbilled inventory but exclusive of work in process, inventory which is obsolete, unsaleable or damaged and crating material), with value defined as the lower of cost or market value; provided, however, that unbilled inventory shall not be included in eligible inventory after January 31, 2020; provided, further, that outstanding borrowings against inventory shall not at any time exceed an aggregate of Five Million and 00/100 Dollars ($5,000,000); plus, in Bank’s sole discretion, a percentage of the value of Borrower’s properly margined unencumbered equipment, such percentage to be determined by Bank in its sole discretion, as evidenced by the equipment appraisal delivered to Bank pursuant to Section 4.12. All of the foregoing shall be determined by Bank upon receipt and review of all collateral reports required hereunder and such other documents and collateral information as Bank may from time to time require. Borrower acknowledges that said borrowing base was established by Bank with the understanding that, among other items, the aggregate of all returns, rebates, discounts, credits and allowances for the immediately preceding three (3) months at all times shall be less than five percent (5%) of Borrower’s gross sales for said period. If such dilution of Borrower’s accounts for the immediately preceding three (3) months at any time exceeds five percent (5%) of Borrower’s gross sales for said period, or if there at any time exists any other matters, events, conditions or contingencies which Bank reasonably believes may affect payment of any portion of Borrower’s accounts, Bank, in its sole discretion, may reduce the foregoing advance rate against Eligible Accounts Receivable to a percentage appropriate to reflect such 2 https://www.sec.gov/Archives/edgar/data/55529/000119312519314689/d846452dex101.htm 2/17


 
12/16/2019 EX-10.1 additional dilution and/or establish additional reserves against Borrower’s Eligible Accounts Receivable, provided that the amount of any reserve established by Bank shall have a reasonable relationship to the matter, event, condition or contingency that is the basis for such reserve and shall not be duplicative of any other reserve established and currently maintained.” (d) Section 4.3(c) of the Credit Agreement is hereby amended by deleting the reference to “during any period in which the Senior Funded Debt to EBITDA Ratio is not tested under Section 4.9(b) of this Agreement,” in clause (iii) thereof. (e) Section 4.3 of the Credit Agreement is hereby amended by (i) deleting the word “and” at the end of subsection (g), (ii) re-lettering subsection (h) as subsection (j) and (iii) adding new subsections (h) and (i) as follows: “(h) on the last business day of each calendar week, a forecast of cash flows of the Borrower for the following thirteen-week period; (i) not later than 30 days after the end of each calendar month, a completed and fully executed Borrowing Base Certificate together with all supporting schedules and calculations and, upon request by Bank, copies of any executed acknowledgment letters in favor of Bank; and”. (f) Section 4.9 of the Credit Agreement is hereby amended and restated in its entirety as follows: “SECTION 4.9. FINANCIAL CONDITION. Maintain Borrower’s financial condition as follows using GAAP consistently applied and used consistently with prior practices (except to the extent modified by the definitions herein): (a) Minimum Monthly Liquidity as of the end of each calendar month not less than (i) during the period from the Eighth Amendment Effective Date through January 31, 2020, $1,500,000 and (ii) thereafter, $3,000,000; with “Minimum Monthly Liquidity” defined as the “Total Borrowing Base Availability” as indicated on the Borrowing Base Certificate for such calendar month. (b) Minimum EBITDA for the Borrower and its Subsidiaries on a consolidated basis at all times during each fiscal quarter, commencing with the fiscal quarter ending April 30, 2020, equal to not less than (i) for the fiscal quarter ending April 30, 2020, determined for the one-quarter period then ended, $315,000, (ii) for the fiscal quarter ending July 31, 2020, determined for the two-quarter period then ended, $1,115,000, (iii) for the fiscal quarter ending October 31, 2020, determined for the three-quarter period then ended, $2,175,000, (iv) for the fiscal quarter ending January 31, 2021, determined for the four-quarter period then ended, $3,040,000. As used herein, “EBITDA” means consolidated net income determined in accordance with GAAP, consistently applied, less income or plus loss from discontinued operations and extraordinary items, plus income taxes, plus interest expense, plus depreciation, depletion, and amortization, all to the extent included in the determination of consolidated net income. For purposes of this Section 4.9(c), EBITDA may be increased by scheduled one-time non-recurring addbacks in an amount not to exceed $250,000.” 3 https://www.sec.gov/Archives/edgar/data/55529/000119312519314689/d846452dex101.htm 3/17


 
12/16/2019 EX-10.1 (g) Article IV of the Credit Agreement is hereby amended by adding new Sections 4.11 and 4.12 as follows: “SECTION 4.11. REPATRIATION. Initiate no later than December 31, 2019 a cash repatriation in an amount not less than $4,000,000, calculated on a pre-tax basis.” “SECTION 4.12. APPRAISALS. Provide to Bank the following, in each case to be prepared by a Person acceptable to Bank in its sole discretion, and at the expense of Borrower: (a) as soon as available, but in any event within sixty (60) days after the Eighth Amendment Effective Date, an appraisal of all equipment of Borrower, (b) at any time upon request by Bank, but not more than two (2) times per calendar year, an appraisal of all inventory of Borrower and (c) at any time upon request by Bank, but not more than two (2) times per calendar year, a field examination of Borrower. (h) Section 5.6 of the Credit Agreement is hereby amended and restated in its entirety as follows: “SECTION 5.6. DIVIDENDS, DISTRIBUTIONS. Declare or pay any dividend or distribution either in cash, stock or any other property on Borrower’s stock now or hereafter outstanding, nor redeem, retire, repurchase or otherwise acquire any shares of any class of Borrower’s stock now or hereafter outstanding, except for (a) dividends and distributions made under Borrower’s restricted stock compensation plan, long-term incentive plan or directors’ compensation plan and (b) cash dividends and distributions from the Borrower to its owners, so long as (a) no event of default or event which, with notice or the passage of time, will constitute an event of default has occurred and is continuing or will result therefrom (giving effect thereto on a pro forma basis as if such payment were made on the first day of the fiscal quarter ending April 30, 2020) and (b) the Fixed Charge Coverage Ratio, calculated as of the last day of the immediately preceding calendar month, for the twelve-month period then ended, is greater than 2.50. As used herein, “Fixed Charge Coverage Ratio” means for the Borrower and its Subsidiaries, as of any date of determination, the ratio of (a) EBITDA for the twelve-month period then ended plus lease expense and rent expense for such period, minus income taxes paid, and dividends, withdrawals, and other distributions made, in such period, to (b) the sum of interest expense, lease expense, rent expense for such period, plus the current portion of long term debt, and the current portion of capitalized lease obligations required to have been made during such period (whether or not such payments are actually made).” (i) Section 6.1(c) of the Credit Agreement is hereby amended and restated in its entirety as follows: “(c) [Reserved].” 4 https://www.sec.gov/Archives/edgar/data/55529/000119312519314689/d846452dex101.htm 4/17


 
12/16/2019 EX-10.1 (j) Section 6.1(d) of the Credit Agreement is hereby amended by deleting the reference to “(excluding Section 4.9(a))”. (k) Annex I (Certain Definitions) of the Credit Agreement is hereby amended by adding the following new definitions in appropriate alphabetical order: ““Borrowing Base Certificate” means a certificate substantially in the form of Exhibit B or in such other form as determined from time to time by Bank in its sole discretion.” ““Eighth Amendment Effective Date” means December 13, 2019.” ““Eligible Accounts Receivable” (a) means trade accounts created in the ordinary course of Borrower’s business, upon which Borrower’s right to receive payment is absolute and not contingent upon the fulfillment of any condition whatsoever, and in which Bank has a perfected security interest of first priority and (b) shall not include: (i) any account that has been outstanding more than (A) three times Borrower’s standard selling terms or (B) 60 days past due or 90 days from the date of the invoice, whichever is less; (ii) that portion of any account for which there exists any right of setoff, defense or discount (except regular discounts allowed in the ordinary course of business to promote prompt payment) or for which any defense or counterclaim has been asserted; (iii) that portion of any account which represents an obligation of any state or municipal government or of the United States government or any political subdivision thereof (except accounts which represent obligations of the United States government and for which the assignment provisions of the Federal Assignment of Claims Act, as amended or recodified from time to time, have been complied with to Bank’s satisfaction) that exceeds ten percent (10%) of Borrower’s total accounts; (iv) any account which represents an obligation of an account debtor located in a foreign country, except to the extent any such account, in Bank’s determination, is supported by a letter of credit or insured under a policy of foreign credit insurance, in each case in form, substance and issued by a party acceptable to Bank; (v) any account which arises from the sale or lease to or performance of services for, or represents an obligation of, an employee, affiliate, partner, member, parent or subsidiary of Borrower; (vi) that portion of any account, which represents interim or progress billings or retention rights on the part of the account debtor; 5 https://www.sec.gov/Archives/edgar/data/55529/000119312519314689/d846452dex101.htm 5/17


 
12/16/2019 EX-10.1 (vii) that portion of all “bill and hold” receivables that exceeds fifty percent (50%) of Borrower’s total accounts, provided that, on and after February 1, 2020, any “bill and hold” receivables that are not subject to an acknowledgment letter in favor of Bank substantially in the form of Exhibit A shall be excluded from Eligible Accounts Receivable; (viii) any account which represents an obligation of any account debtor when twenty percent (20%) or more of Borrower’s accounts from such account debtor are not eligible pursuant to (i) above; (ix) that portion of any account from an account debtor which represents the amount by which Borrower’s total accounts from said account debtor exceeds twenty-five percent (25%) of Borrower’s total accounts; or (x) any account deemed ineligible by Bank when Bank, in its sole discretion, deems the creditworthiness or financial condition of the account debtor, or the industry in which the account debtor is engaged, to be unsatisfactory.” ““Senior Funded Debt” means Funded Debt, but excluding any debt that is contractually subordinated in right of payment to the Line of Credit, either Term Loan or any outstanding borrowings thereunder.”” (l) The Credit Agreement is hereby amended by (i) adding an Exhibit A thereto substantially in the form of Exhibit A hereto and (ii) adding an Exhibit B thereto substantially in the form of Exhibit B hereto. Section 2. Specific Amendments to Line of Credit Note. The parties hereto agree that the Line of Credit Note is amended as follows: (a) The Section entitled “DEFINITIONS” of the Line of Credit Note is hereby amended by: (i) adding the following sentence to the end of the first paragraph thereof: “Capitalized terms used herein and not defined herein shall have the meanings assigned thereto in the Credit Agreement.”; and 6 https://www.sec.gov/Archives/edgar/data/55529/000119312519314689/d846452dex101.htm 6/17


 
12/16/2019 EX-10.1 (ii) replacing the table in the definition of “Applicable Margin” with the following table: Senior Funded Debt to Applicable Margin for Daily EBITDA One Month LIBOR Applicable Margin for Tier Ratio Advances Prime Rate Advances I < 2.50x 1.50% 0.50% II >2.50x but £ 3.50x 2.25% 0.75% III >3.50x but £ 4.25x 3.00% 1.00% IV >4.25x 3.75% 1.25% Section 3. Limited Amendment. Except as expressly set forth in this Amendment, the Credit Agreement, the Line of Credit Note, and each other Loan Document shall continue to be, and shall remain, in full force and effect. Except as expressly set forth in this Amendment, this Amendment shall not be deemed or otherwise construed (a) to be a waiver of, or consent to or a modification or amendment of, any other term or condition of the Credit Agreement, the Line of Credit Note, or any other Loan Document, (b) to prejudice any other right or remedies that Bank may now have or may have in the future under or in connection with the Credit Agreement, the Line of Credit Note, or any other Loan Document, as such documents may be amended, restated or otherwise modified from time to time, (c) to be a commitment or any other undertaking or expression of any willingness to engage in any further discussion with the Borrower or any other person, firm or corporation with respect to any waiver, amendment, modification or any other change to the Credit Agreement, the Line of Credit Note, or any other Loan Document or any rights or remedies arising in favor of the Bank under or with respect to any such documents or (d) to be a waiver of, or consent to or a modification or amendment of, any other term or condition of any other agreement by and among the Borrower, on the one hand, and the Bank, on the other hand. By its execution hereof, Borrower hereby acknowledges and agrees that this Amendment is a “Loan Document” and failure to comply with this Amendment shall constitute an Event of Default under the Credit Agreement. Section 4. Conditions to Effectiveness. This Amendment shall become effective as of the date when the following conditions have been met: (a) The Bank shall have received an original of this Amendment duly executed by the Borrower, and by the Bank (whether such parties shall have signed the same or different copies); (b) The Bank shall have been reimbursed by Borrower for all reasonable fees and third-party out-of-pocket charges and other expenses incurred in connection with this Amendment and the transactions contemplated thereby or otherwise due and owing pursuant to the Loan Documents as of the date hereof, including, without limitation, (y) the reasonable attorneys’ fees and expenses of Womble Bond Dickinson (US) LLP, as counsel to the Bank and (z) lien searches, title and recordation fees, if any; 7 https://www.sec.gov/Archives/edgar/data/55529/000119312519314689/d846452dex101.htm 7/17


 
12/16/2019 EX-10.1 (c) The Bank shall have received from the Borrower an amendment fee in the amount of $20,000.00 which fee shall be fully earned by the Bank and payable on the date of this Amendment; (d) The Bank shall have received the Borrower’s updated financial projections/statements; (e) The Bank shall have received any other documents, agreements and instruments reasonably requested by the Bank in connection with the execution of this Amendment and the transactions contemplated thereby; and (f) The Bank shall have received a pro forma Borrowing Base Certificate from the Borrower. Section 5. Representations and Warranties. After giving effect to the amendments set forth herein, Borrower hereby represents and warrants to the Bank that: (a) Each of the representations and warranties set forth in the Credit Agreement, the Line of Credit Note and the other Loan Documents is true and correct in all material respects as of the date hereof as if fully set forth herein (except for any representation and warranty made as of an earlier date, which representation and warranty shall remain true and correct as of such earlier date); (b) No Event of Default has occurred and is continuing as of the date hereof; (c) The execution, delivery, and performance of this Amendment have been authorized by all requisite corporate action; (d) The execution, delivery and performance by the Borrower of this Amendment, and compliance by it with the terms hereof and thereof, do not and will not (i) violate any provision of its certificate of incorporation, bylaws, or other applicable formation or organizational documents, (ii) contravene any requirement of law applicable to it, (iii) conflict with, result in a breach of or constitute (with notice, lapse of time or both) a default under any material indenture, mortgage, lease, agreement, contract or other instrument to which it is a party, by which it or any of its properties is bound or to which it is subject, or (iv) except for the Liens granted in favor of the Bank, result in or require the creation or imposition of any Lien upon any of its properties, revenues or assets; except, in the case of clauses (ii) and (iii) above, where such violations, conflicts, breaches or defaults, individually or in the aggregate, could not reasonably be expected to have a material adverse effect; and (e) This Amendment constitutes the legal, valid and binding obligation of the Borrower, enforceable against it in accordance with its terms, except as enforceability may be limited by bankruptcy, insolvency, reorganization, moratorium or other similar laws affecting creditors’ rights generally, by general equitable principles or by principles of good faith and fair dealing (regardless of whether enforcement is sought in equity or at law). 8 https://www.sec.gov/Archives/edgar/data/55529/000119312519314689/d846452dex101.htm 8/17


 
12/16/2019 EX-10.1 Section 6. Confirmation of all Loan Documents. By its execution hereof, the Borrower hereby expressly (a) consents to the amendments set forth in this Amendment, (b) reaffirms all of its respective covenants, representations, warranties and other obligations set forth in the Credit Agreement, the Line of Credit Note and each of the other Loan Documents and (c) acknowledges, represents and agrees that its respective covenants, representations, warranties and other obligations set forth in the Credit Agreement, the Line of Credit Note and each of the other Loan Documents remain in full force and effect. For the avoidance of doubt, all financial covenants contained in Section 4.9 of the Credit Agreement prior to the execution of this Amendment are hereby superseded and replaced by the terms of this Amendment and are no longer in effect. Section 7. Expenses. The Borrower shall reimburse the Bank upon demand for all reasonable and documented costs and expenses (including attorneys’ fees) incurred by the Bank and outstanding as of the date hereof, including, without limitation, costs incurred in connection with the preparation, negotiation, execution, delivery, administration and enforcement of this Amendment and the other agreements and documents executed and delivered in connection herewith, whether or not this Amendment becomes effective. Section 8. Certain References. On and after the effectiveness of this Amendment, each reference in the Credit Agreement, the Line of Credit Note or any other Loan Document shall mean and be a reference to the Credit Agreement, the Line of Credit Note and such other Loan Document as amended by this Amendment. Section 9. Counterparts. This Amendment may be executed in multiple counterparts, each of which shall be deemed an original, but all of which shall constitute one and the same agreement, and the signature pages from any counterpart may be appended to any other counterpart to assemble fully- executed counterparts. Counterparts of this Amendment may be exchanged via electronic means, and a facsimile of any party’s signature shall be deemed to be an original signature for all purposes. This Amendment shall be binding upon and shall inure to the benefit of the parties hereto and their respective successors and assigns. Section 10. Definitions. All capitalized terms used herein and not otherwise defined shall have the respective meanings provided to such terms in the Credit Agreement, as amended hereby. Section 11. GOVERNING LAW. THIS AMENDMENT AND THE RIGHTS AND OBLIGATIONS OF THE PARTIES HEREUNDER SHALL BE GOVERNED BY, AND CONSTRUED IN ACCORDANCE WITH, THE LAWS OF THE STATE OF NORTH CAROLINA APPLICABLE TO CONTRACTS EXECUTED, AND TO BE FULLY PERFORMED, IN SUCH STATE. [Signature Pages Follow] 9 https://www.sec.gov/Archives/edgar/data/55529/000119312519314689/d846452dex101.htm 9/17


 
12/16/2019 EX-10.1 IN WITNESS WHEREOF, the Borrower and the Bank, on the day and year first written above, have caused this Amendment to be executed under seal. BORROWER: KEWAUNEE SCIENTIFIC CORPORATION By: /s/ Donald T. Gardner III Name: Donald T. Gardner III Title: CFO/Corporate Secretary [Eighth Amendment – Kewaunee Scientific Corporation] https://www.sec.gov/Archives/edgar/data/55529/000119312519314689/d846452dex101.htm 10/17


 
12/16/2019 EX-10.1 BANK: WELLS FARGO BANK, NATIONAL ASSOCIATION By: /s/ Michael J. Bennett Name: Michael J. Bennett Title: Senior Vice President [Eighth Amendment – Kewaunee Scientific Corporation] https://www.sec.gov/Archives/edgar/data/55529/000119312519314689/d846452dex101.htm 11/17


 
12/16/2019 EX-10.1 Exhibit A FORM OF BILL/HOLD ACKNOWLEDGMENT LETTER BILL AND HOLD LETTER [SELLER’S NAME] ______________, 201__ [CUSTOMER’S NAME] __________________________ __________________________ Attention:________________ Dear Customer: From time to time you (the “Customer”) may request that the undersigned (the “Seller”) manufacture and produce certain goods for future shipment to you. This will confirm the agreement of Customer and Seller that, notwithstanding anything to the contrary contained in any purchase order, invoice or other agreement between Customer and Seller, title to such goods manufactured and produced by Seller for Customer and risk of loss as to such goods passes to Customer when Seller has completed production of the goods covered by Customer’s order and the goods have been invoiced by Seller to Customer, notwithstanding that the goods so sold may remain on the premises of Seller or otherwise in its control or possession. Such goods are held for the account of Customer and at its risk and each invoice with respect to such goods issued to Customer by Seller represents a definitive and final sale and Customer shall pay the same when due, regardless of whether the goods have been shipped or delivered to Customer as of such time or are otherwise accepted by Customer. Customer agrees that, except as provided below, in no event shall Customer, or any person claiming by, through or under it, offset or withhold payment in respect of any account for any offset, claim, defense, counterclaim, abatement, suspension, recoupment or deduction which Customer may have against Seller for any amounts which may now or hereafter be due to Customer from Seller for any reason, except that Customer may, in the ordinary course of business assert any bona fide offsets or deductions it may lawfully have only against accounts due to the Customer by reason of the delivery to Customer by Seller of defective or non-conforming goods to the extent that the basis for the offset or deduction arises out of the same transaction giving rise to the account due which is subject to the asserted offset or deduction.. https://www.sec.gov/Archives/edgar/data/55529/000119312519314689/d846452dex101.htm 12/17


 
12/16/2019 EX-10.1 The fact that Customer has limited its setoff and recoupment rights against accounts due to Seller shall not limit any rights or remedies Customer may have against Seller or any of its other assets. Customer waives any right that it may have under any Federal, State or other law, including, without limitation, all rights under Section 553 of the U.S. Bankruptcy Code, to assert any such rights. Seller may store the goods at its premises or in leased warehouse space. The goods will be shipped to Customer from time to time at its request upon reasonable prior notice in accordance with Seller’s policies as in effect from time to time. All out-of-pocket expenses incurred by Seller for storage, insurance or disposal in connection with the goods manufactured for Customer by Seller are to be billed by Seller to Customer in accordance with Seller’s policies as in effect from time to time. https://www.sec.gov/Archives/edgar/data/55529/000119312519314689/d846452dex101.htm 13/17


 
12/16/2019 EX-10.1 Seller would appreciate the confirmation of the agreement of Customer to the above arrangements by signing and returning to Seller the enclosed copy of this letter. The agreement of Customer in this letter will be binding on its successors and assigns. In making loans to Seller based on the accounts payable by Customer to Seller from such sales, Wells Fargo Bank, National Association, the lender to Seller, is relying on the agreements of Customer in this letter and the terms of this letter will inure to the benefit of such lender and its successors and assigns (including any other lender that refinances or replaces its financing) and such lender and successors and assigns will be entitled to enforce the terms hereof directly. The terms of this letter may not be modified by course of dealing or otherwise than in writing signed by Seller and approved in writing by its lender. We would like to take this opportunity to thank you for your continued business. Very truly yours, [SELLER’S NAME] By: Name: Title: AGREED: [CUSTOMER’S NAME] By: Name: Title: https://www.sec.gov/Archives/edgar/data/55529/000119312519314689/d846452dex101.htm 14/17


 
12/16/2019 EX-10.1 Exhibit B FORM OF BORROWING BASE CERTIFICATE Kewaunee Scientific Corporation—Borrowing Base Certificate for period ending: [_____] in 000s Accounts Receivable Source Document Gross A/R (Domestic) [_____] Less: Ineligible A/R a. Past Dues [_____] b. Past Due Credits [_____] c. Cross Age [_____] d. Intercompany [_____] e. Foreign [_____] f. Retainage [_____] g. Government Receivables [_____] h. Advance Sales (FE and ENG) [_____] i. Bill and Hold (B&H Letters on File) [_____] Total A/R Ineligibles [_____] Net Eligible A/R [_____] Advance Rate [__]% Available A/R [_____] Inventory Gross Inventory (Domestic) [_____] Plus: Bill & Hold Inventory [_____] Plus: Unbilled Inventory [_____] Less: Ineligible Inventory a. Obsolescence/Excess [_____] b. WIP [_____] c. Crating Materials [_____] _____________ Total Inventory Ineligibles [_____] Net Eligible Inventory [_____] Advance Rate [__]% Eligible Inventory [_____] https://www.sec.gov/Archives/edgar/data/55529/000119312519314689/d846452dex101.htm 15/17


 
12/16/2019 EX-10.1 Machinery and Equipment Appraised M&E [_____] Advance Rate [__]% Eligible M&E [ ] TOTAL BB Availability $ [_____] Plus: Outstanding Letters of Credit [_____] Plus: Outstanding Loan Balance [_____] Total Loans and SLCs Outstanding [_____] Plus: Minimum Additional Liquidity [_____] Total Required Borrowing Base Assets [_____] Excess / (Limited) Availability $ [_____] Line of Credit Commitment [_____] Excess / (Suppressed) Availability ([_____]) Calculations Gross B&H A/R [_____] B&H Cap (50% of total AR) [_____] Net Eligible B&H A/R (Lesser of 50% or Gross Amount) [_____] Gross B&H Inv [_____] B&H Cap (50% of total Inv.) [_____] Net Eligible B&H Inv. (Lesser of 50% or Gross Amount) [_____] Gross Unbilled Inv [_____] B&H Cap (50% of total Inv.) [_____] Net Eligible Unbilled Inv. (Lesser of 50% or Gross Amount) [_____] Gross Government Receivables A/R [_____] Govt AR Cap (10% of total AR) [_____] Net Eligible Govt A/R (Lesser of 10% or Gross Amount) [_____] https://www.sec.gov/Archives/edgar/data/55529/000119312519314689/d846452dex101.htm 16/17


 
12/16/2019 EX-10.1 Bill and Hold Schedule Company Name Invoice # Amount https://www.sec.gov/Archives/edgar/data/55529/000119312519314689/d846452dex101.htm 17/17


 
October 28, 2019 Mr. Mandar Ranade rmandaar@hotmail.com Dear Mandar, I am pleased to confirm our offer of employment with Kewaunee Scientific Corporation as our Vice President of Information Technology, reporting to Tom Hull, President and CEO. In this position, your starting salary will be $17,500 monthly ($210,000.00 annualized). Following our normal practices, this offer is made contingent upon your passing a pre-employment drug test and background screen. In addition to your salary, we offer an attractive benefits package, which includes a health care program, dental plan, life insurance, disability income program, 401(k) retirement savings plan, flexible spending accounts, on-site Nurse Practitioner program, as well as other benefits provided to full-time Associates. A copy of the salaried fringe benefit document is attached for your reference. If you should have any questions concerning the fringe benefits, please feel free to contact me. We are also delighted to offer you extended benefits based on your role in the organization over and above our standard benefits package. These benefits include participation in our annual cash bonus program at a rate of 30% of your annual salary, participation in our long term equity incentive program at a rate of 30% of your annual salary and participation in the Company’s 409(a) deferred compensation program. You will also be entitled to four weeks of vacation upon hire. We also are delighted to offer you a sign-on bonus of $70,000 payable 30 days after your start date as well as assistance with relocation as outlined in a separate document. Pre-employment Requirements As mentioned above, your employment is contingent upon fulfilling a pre-employment drug screen and background check. Pursuant to the Immigration and Nationality Act, our Company is required to verify the identity and employment authorization of all new hires. In order to comply with this legal obligation, we must complete an Employment Eligibility Verification Form (I-9) within your first three days of hire. Kewaunee also participates in the E-Verify program. Please call me if you have any questions regarding our employment authorization process. You will also be required to read and sign the acknowledgements for the following documents and policies:  Kewaunee Associate Handbook Acknowledgement and Agreement  Agreement Concerning Employee Inventions and Confidential Information  Alcohol-Free and Drug-Free Workplace Policy Acknowledgement Form  Conflict of Interest Policy  Policy on Sensitive Payments  Standards of Conduct and Corrective Actions P. O. BOX 1842, STATESVILLE, NORTH CAROLINA 28687-1842 ● 2700 WEST FRONT STREET, STATESVILLE, NORTH CAROLINA 28677-2927 PHONE 704-873-7202 ● FAX 704-873-1275


 
Mr. Ranade Page 2 Pay Schedule Kewaunee exempt Associates are paid on a monthly schedule, the last day of the month. Direct deposit of your payroll check is required; please bring a voided check with you on your start date. Hours and Holiday Schedule Corporate Office hours in Statesville, NC are 8:00 a.m. – 5:00 p.m. Your normal work schedule will be Monday through Friday 8:00 a.m. – 5:00 p.m. Due to the nature of your position, you will be required to work additional hours. A holiday schedule is enclosed for your reference. Associate Handbook You will be provided a copy of the Kewaunee Associate Handbook. It is your responsibility to familiarize yourself with the policies and procedures that apply to you as an Associate of Kewaunee. Mandar, we think this is a very comprehensive and competitive offer, reflecting our opinion of your potential in our Company. We believe that you could make a great contribution to our Company, have fun, and enjoy real personal growth in the years ahead. Should you have any questions concerning this offer, please call me. Please confirm your acceptance by signing a copy of this letter, indicating your start date, and return it to my attention. We appreciate your response within five business days or sooner. Best Regards, Elizabeth Phillips, SPHR, SHRM-SCP Vice President of Human Resources Enclosures Copy to: Tom Hull, President and CEO Personnel File I, Mandar Ranade, accept the terms and conditions of this offer, and I will report to work on __________________________, 2019. Signed ________________________________________ _______________________________10/29/2019 Mandar Ranade Date


 
October 28, 2019 Mr. Mandar Ranade rmandaar@hotmail.com Dear Mandar, We hope that you are excited about our offer of employment and that the relocation assistance described below will be helpful as you are considering your decision. As a result of relocation, Kewaunee Scientific Corporation will provide assistance with relocation expenses acquired during your move from Milwaukee, Wisconsin to a location closer to Statesville / Charlotte, N.C. As part of our offering, we are extending an amount of $30,000 (net) for your moving and relocation expenses. Your relocation expenses can include transportation costs, the move of household goods, realtor fees, etc., The amount will be paid as needed. Additional Relocation Benefits In further consideration of your move closer to Statesville we are offering temporary housing allowance of $2,000 per month maximum for up to 6 months. We can provide recommendations and assist you with this process. Additionally, to ease your transition and knowing that your family will not be moving until the spring, 2020, we are offering an allowance of 2 trips per month to Wisconsin for up to 6 months. Repayment Provision Should you voluntarily resign, or be terminated for cause from the company within the first three years, we would be entitled to recoup monies paid to you relating to moving expenses. The pay back would be proportionate to the time worked and you would assume 1/3 of the costs for each year short of the three years completion. If you have any questions regarding the relocation reimbursement arrangement described please let me know. We hope that you are pleased with this arrangement and that it eases the challenges of relocating. Sincerely, Elizabeth D. Phillips, Vice President, Human Resources


 

Exhibit 31.1
CERTIFICATION
I, Thomas D Hull III, certify that:
1.
I have reviewed this Quarterly Report on Form 10-Q of Kewaunee Scientific Corporation;
2.
Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3.
Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4.
The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
a)
Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
b)
Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
c)
Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
d)
Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
5.
The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
a)
All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
b)
Any fraud, whether or not material, that involves management or other employees who have a    significant role in the registrant’s internal control over financial reporting.  
/s/ Thomas D. Hull III
Thomas D. Hull III
President and Chief Executive Officer
Date: December 16, 2019  

 
Exhibit 31.2
CERTIFICATION
I, Donald T. Gardner III, certify that:
1.
I have reviewed this Quarterly Report on Form 10-Q of Kewaunee Scientific Corporation;
2.
Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3.
Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4.
The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
a)
Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
b)
Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
c)
Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
d)
Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
5.
The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
a)
All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
b)
Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.  
/s/ Donald T. Gardner III
Donald T. Gardner III
Vice President, Finance and Chief Financial Officer
Date: December 16, 2019  





 
Exhibit 32.1
CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER
PURSUANT TO 18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
In connection with the Quarterly Report on Form 10-Q of Kewaunee Scientific Corporation (the “Company”) for the period ended October 31, 2019, I, Thomas D. Hull III, President and Chief Executive Officer of the Company, hereby certify pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to my knowledge:
(1)
such Form 10-Q of the Company for the period ended October 31, 2019, fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
(2)
the information contained in such Form 10-Q of the Company for the period ended October 31, 2019, fairly presents, in all material respects, the financial condition and results of operations of the Company.
Date: December 16, 2019
 
/s/ Thomas D. Hull III
Thomas D. Hull III
President and Chief Executive Officer
 


 
Exhibit 32.2
CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER
PURSUANT TO 18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
In connection with the Quarterly Report on Form 10-Q of Kewaunee Scientific Corporation (the “Company”) for the period ended October 31, 2019, I, Donald T. Gardner III, Vice President, Finance and Chief Financial Officer of the Company, hereby certify pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to my knowledge:
(1)
such Form 10-Q of the Company for the period ended October 31, 2019, fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
(2)
the information contained in such Form 10-Q of the Company for the period ended October 31, 2019, fairly presents, in all material respects, the financial condition and results of operations of the Company.
Date: December 16, 2019
 
/s/ Donald T. Gardner III
Donald T. Gardner III
Vice President, Finance and
Chief Financial Officer